KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables: 2009-2024

Historic Receivables for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $328.8 million.

  • Halozyme Therapeutics' Receivables rose 21.10% to $346.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 39.12%. This contributed to the annual value of $328.8 million for FY2024, which is 39.77% up from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Receivables is $328.8 million, which was up 39.77% from $235.2 million recorded in FY2023.
  • Halozyme Therapeutics' Receivables' 5-year high stood at $328.8 million during FY2024, with a 5-year trough of $92.1 million in FY2021.
  • Its 3-year average for Receivables is $265.0 million, with a median of $235.2 million in 2023.
  • Its Receivables has fluctuated over the past 5 years, first fell by 12.88% in 2021, then soared by 150.85% in 2022.
  • Halozyme Therapeutics' Receivables (Yearly) stood at $105.7 million in 2020, then dropped by 12.88% to $92.1 million in 2021, then soared by 150.85% to $231.1 million in 2022, then rose by 1.79% to $235.2 million in 2023, then soared by 39.77% to $328.8 million in 2024.